Yieldmax Meta Option Income Strategy ETF (FBY)

Signatera™ Receives Regulatory Approval in Japan for Colorectal CancerJune 24, 2026 5:00 AM
Business WireFirst PMDA-approved molecular residual disease (MRD) test in Japan, supporting the use of Signatera in the adjuvant settingCommercia

110M+ volume first hour

BLA submission triggers at hazard ratio at or below 0.6. Phase 2 median OS for the exact Phase 3 formulation was 16.6 months versus approximately 8 months for TPC, implied hazard ratio of approximately 0.48. Well inside the submission zone.
Enrollment: 315 screened and 230 enrolled as of May

https://media0.giphy.com/media/v1.Y2lkPTZjMDliOTUybnQzZTJ0Mzc5Z255ZTN3OXcweGdpZmE5emhhNTljaDFoYjhncXIyMCZlcD12MV9pbnRlcm5hbF9naWZfYnlfaWQmY3Q9Zw/FoH28ucxZFJZu/giphy.gifhttps://media1.giphy.com/media/v1.Y2lkPTZjMDliOTUyNDlhaGRnenBrODJ5aXd3Z3Y5c3E3NmV6eXo1c3ZramF2amV6eXRsOCZlcD12MV9pbnRlcm5hbF9naWZfYn

AI technology is coming. It's a new day. Infrastructure that will change everything. Like I've said before, expect the unexpected.

2 ideas I have!

1, waiting for news of the creation of the SWF and adding F-2 and other Gov investments to it. All those lending agencies, Farmer Mac, Freddie Mac, Fannie Mae etc into the SWF. The news released on Americas 250 birthday the release plan. There's his $1 Trillion Market

Morningstar Sustainalytics Enhances Physical Climate Risk Capabilities with XDI and VeridionJune 24, 2026 4:36 AM
Business Wire Dataset is designed to translate asset-level climate hazards into risk metrics for investors Morningstar Sustainalytics, a leading provider of

Just keep the apology short and to the point. I think we are on the same team.

Up 10% first 100m volume

Fortune Minerals Announces Results of Annual and Special Meeting of ShareholdersJune 24, 2026 4:20 AM
Business Wire Fortune Minerals Limited (TSX: FT) (OTCQB: FTMDF) (“Fortune” or the “Company”) (

Volume is 85M, .048 price.

4:20 AM.

Tom Terrific! You got this!..Something is Up! I scolled down after reading it was Norma Garcia being awarded those shares that she could sell at .368 or so ,,something like thati Something good.IMO.In our opinion..Trader..You on this? Ya just dont keep rearding shares without a event thats going t

$WNW Looking for a PM move here...Getting Volume early 3.74

How so?

Is Iran really over

$WNW Looking for a PM move here...Getting Volume early

Thanks! Seems realistic indeed. Any price targets for next week, or eom?

Cheers & have a good week!

Mexedia announces the reduction of its shareholding in Telvantis to 49%

full statement at mexida website under press releases. Any opinions on weather this is good or bad for us?

d_stock
@d_stock07734
$NWBO

$NWBO probably can produce DC vaccines pulsed with either allogenic tumor lysate or synthetic peptides from a biobank. That means that surgery may not be needed.

But cancer patients have to go through leukapheresis procedure to

Planning to add more tomorrow - Ackman’s prediction on timing seems to align well

Elite, please uplist to the Nasdaq.
My tax free account is waiting for you with open arms.
I can’t buy it in my tax free account while it’s OTC and I already maxed out how much I can buy as there is a limit.

Based on the limited information available, this appears to mean that drug makers may, in suitable cases, be able to achieve approval based on one rigorous, well-controlled pivotal Phase 3 trial plus confirmatory evidence, rather than multiple pivotal trials.
In late-stage development, drugma

4:01 AM, and already .045 with 20M

shares traded. Up 9% and not looking back.

Coretura and Accenture Join Forces to Reinvent the Development of Software-Defined Commercial VehiclesJune 24, 2026 3:59 AM
Business Wire Engineering collaboration brings together deep automotive expertise and the ambition to provide one software platform, lang

European Semiconductor Firms Seek Integrated EcosystemsJune 24, 2026 4:00 AM
Business Wire Sovereignty goals, supply chain pressures and AI-driven operations are accelerating demand for end-to-end semiconductor partnerships, ISG Provider Lens® report